According to Kezar Life Sciences's latest financial reports the company has ยฃ0.12 Billion in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2022-12-31 | ยฃ0.22 B | 48.1% |
2021-12-31 | ยฃ0.15 B | 49.81% |
2020-12-31 | ยฃ0.10 B | 72.77% |
2019-12-31 | ยฃ59.63 M | -29.53% |
2018-12-31 | ยฃ84.63 M | 124.14% |
2017-12-31 | ยฃ37.76 M | 378.02% |
2016-12-31 | ยฃ7.89 M |